- Carolyn Paradise, MD, Joins Intezyne as Acting Chief Medical Officer -
- Tim Coan Joins Intezyne as Chief Financial Officer -
TAMPA, Fla., July 10, 2014 (GLOBE NEWSWIRE) -- Intezyne Technologies, a privately held drug development company dedicated to improving the treatment of cancer, announced it has expanded its leadership team with two appointments: Carolyn M. Paradise, MD, has joined Intezyne as Acting Chief Medical Officer, and Tim Coan has been appointed Intezyne's Chief Financial Officer. Dr. Paradise has a 28-year career in developing oncology therapies, including three that received FDA approval. Mr. Coan has a two-decade history in the financial industry, most recently as a Partner at Deerfield Partners. Both Dr. Paradise and Mr. Coan will report directly to Habib Skaff, PhD, Chairman, President and Chief Executive Officer of the Company.
"Upon completion of our next round of financing, we will launch a robust clinical development program to determine which opportunities are most promising for Phase 3 development. Carolyn's expertise in developing oncology drugs and getting them through the regulatory review and approval process both at the FDA and EMA will be extremely valuable in helping establish strong clinical foundations for Intezyne's success," stated Dr. Skaff. "We also are aware the clinical development program we want to implement will require more capital than most private companies can secure from the venture community, therefore tapping the public markets is a likely step in Intezyne's evolution. Yet we want to ensure we enter the public markets at the right time. Tim is highly respected by his peers and the life sciences industry, and Intezyne is fortunate to have captured his interest. Kevin Sill and I are looking forward to working closely with both Carolyn and Tim as we enter this exciting period in the Company's history."
Dr. Paradise has been consulting clients on clinical development strategies after spending six years serving as President and Chief Operating Officer of ARMGO Pharma, Inc. Previously, she served as Senior Vice President and Chief Medical Officer at Aton Pharma, working on the development of Zolinza® (vorinostat) for Cutaneous T-Cell Lymphoma, which was acquired by Merck & Co., Inc. Dr. Paradise spent five years with Cell Therapeutics, Inc., culminating in her position as Executive Vice President, Clinical Operations & Regulatory Affairs, Chief Medical Officer. She was directly involved with the U.S. and EU marketing approvals for Trisenox® (arsenic trioxoide) in relapsed Promyelocytic Leukemia. Dr. Paradise has twice been involved obtaining marketing approvals for Proleukin (interleukin 2), first at Cetus Corporation and subsequently at Chiron after spending several years at Sterling Winthrop Pharmaceutical R&D. Dr. Paradise received her MD from Free University of Brussels, Belgium and completed her fellowship in Hematology/Oncology at the Beth Israel Hospital, Harvard Medical School.
Mr. Coan retired from Deerfield Partners in 2012 after a five-year career identifying new investment opportunities and contributing to a $2 billion portfolio of healthcare investments. He was instrumental in Deerfield's investments in ISTA Pharmaceuticals, Salix, Par Pharmaceuticals, and Alpharma. Mr. Coan joined Deerfield after establishing his reputation for thorough corporate analysis as a healthcare research analyst at several well-regarded investment banks, including Piper Jaffray. Most recently, he advised emerging life sciences companies on their strategic plans and financing options. Mr. Coan received his Bachelor's degree in economics from Trinity College-Hartford and earned his Masters of Business Administration from The College of William and Mary – The Mason School of Business.
About Intezyne Technologies
Intezyne is dedicated to treating cancer better. Intezyne's breakthrough nanotechnology platform, the IVECT™ Method, was invented by the Company's co-founders, Habib Skaff, PhD, and Kevin Sill, PhD, synthetic chemists specializing in nanotechnology and polymer chemistry. IVECT-derived nanoparticles can be generated around a broad array of drugs, from small molecules to peptides/proteins to nucleic acids, making the platform highly versatile in its applicability and scope. These nanoparticles can be enhanced further by adding a desired targeting ligand/receptor to the surface of the nanoparticle. The IVECT-based nanoparticles, therefore, not only dramatically increase the effectiveness of certain anti-cancer therapies, the technology platform also makes possible the creation of completely new therapies. Preclinical work conducted by Intezyne has shown the IVECT-derived anti-cancer nanoparticles preferentially accumulate in tumor cells, thereby sparing the normal healthy cells, and have shown positive preclinical efficacy and safety profiles in multiple cancer models versus best-in-class chemotherapeutic agents. Intezyne currently has three IVECT-based product candidates in development and has conducted numerous product development projects for global pharmaceutical companies. For more information, please visit the Company's website at www.intezyne.com.
CONTACT: Investor and Media Contact Juliane Snowden The Oratorium Group, LLC email@example.com 646-438-9754Source:Intezyne, Inc.